Who Supplies Liraglutide to India from DENMARK

To import finished pharmaceutical formulations containing Liraglutide into India, obtaining an import license from the Directorate General of Foreign Trade (DGFT) is mandatory. The Central Drugs Standard Control Organisation (CDSCO) requires registration of the product, which involves submitting Form 40/41 along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The registration process typically takes 6–12 months, depending on the completeness of the application and compliance with regulatory requirements. Liraglutide formulations under HS Code 30049099 are subject to these regulations to ensure quality, safety, and efficacy.

Imported Liraglutide formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to International Council for Harmonisation (ICH) Zone IV guidelines, is essential to demonstrate product stability under Indian climatic conditions. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported products.

In April 2025, the CDSCO mandated import registration and licensing for all pharmaceutical imports to prevent the sale of unapproved or illegal medicines in the Indian market. This regulation requires compliance with the Drugs and Cosmetics Act and associated rules. Additionally, the Production Linked Incentive (PLI) scheme, introduced in 2020, aims to boost domestic manufacturing and may impact the import of finished formulations, including Liraglutide, by encouraging local production.

India imports finished Liraglutide formulations primarily due to the availability of patented or branded products not manufactured domestically. Specific dosage forms, such as pre-filled pens and cartridges, are often sourced from international markets. Domestic capacity for Liraglutide formulations is limited, leading to a dependency on imports to meet patient needs. The market size for Liraglutide in India is growing, driven by increasing prevalence of Type 2 diabetes and the need for effective management options.

The Basic Customs Duty (BCD) for Liraglutide formulations under HS Code 30049099 is 10%. A Social Welfare Surcharge (SWS) of 10% on BCD is applicable. Integrated Goods and Services Tax (IGST) is levied as per prevailing rates, which are subject to change. There are no specific exemptions or concessional duties for Denmark-origin products under the Most Favored Nation (MFN) tariff. The total landed duty percentage varies based on the IGST rate and other applicable charges.

Denmark, particularly through Novo Nordisk, is a significant supplier of Liraglutide formulations to India. The competitive advantage lies in the availability of patented formulations and specialized dosage forms not produced domestically. Other suppliers include China, Germany, and the United States; however, Denmark's share is notable due to its established presence and quality standards.

India imports Liraglutide formulations from Denmark due to the availability of patented products and specialized dosage forms not manufactured domestically. Denmark's established pharmaceutical industry, particularly through Novo Nordisk, offers high-quality products that meet international standards, fulfilling the unmet demand in the Indian market.

Compared to other origins like China, Germany, and the United States, Denmark offers a competitive advantage in terms of product quality, regulatory compliance, and reliability. Denmark's adherence to stringent GMP standards and its reputation for innovation in diabetes care make it a preferred source for Liraglutide formulations.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. While Denmark has a stable supply chain, Indian importers should consider these factors in their risk management strategies.

1. 1Dual-Sourcing: Engage multiple suppliers to mitigate single-source risk.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letter of Credit (LC) or Documents Against Payment (DAP).
4. 4Minimum Order Quantities (MOQs): Align order sizes with demand forecasts to optimize inventory.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure compliance with regulatory standards and quality expectations.

1. 1DGFT Import License: Obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Submit Form 40/41 along with CoPP, GMP certificate, and stability data.
3. 3Drug Import License: Apply for a license under the Drugs and Cosmetics Act.
4. 4No Objection Certificate (NOC): If applicable, obtain NOC from the Ministry of Health and Family Welfare.
5. 5Customs Broker: Engage a licensed customs house agent for clearance procedures.
6. 6Advance Ruling: Seek advance ruling for HS Code 30049099 to confirm classification and duty rates.

1. 1Certificate of Analysis (CoA): Confirming compliance with Indian Pharmacopoeia standards.
2. 2Certificate of Pharmaceutical Product (CoPP): Indicating product registration in the country of origin.
3. 3Good Manufacturing Practice (GMP) Certificate: Demonstrating compliance with international manufacturing standards.
4. 4Drug Master File (DMF): Providing detailed information on the manufacturing process.
5. 5Stability Data: Adhering to ICH Zone IV guidelines.